Famous Patents
3M employee and church chorister Art Fry needed something to temporarily mark pages in his hymnal. He was in luck because his colleague, Spencer Silver, accidentally developed a glue that was too weak for other purposes. After initially discouraging consumer response, Post-it Notes became a hit in 1979.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8062876 | Method for activating prethrombin-1 Methods for converting prethrombin-1 to thrombin are disclosed. An aqueous solution of prethrombin-1 is applied to oscutarin-C immobilized on a solid support so as to provide from 500 mg to 4000 mg of prethrombin-1 per mL of the solid support and a contact time betw... | 11/22/2011 |
| 7718412 | Hemostatic compositions containing sterile thrombin The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and that is substantially insoluble in the liquid phas... | 05/18/2010 |
| 7473543 | Thrombin compositions Compositions comprising thrombin and methods of preparing them are disclosed. The composition may be in the form of an aqueous solution at pH 5.7-7.4 consisting essentially of 0.1 mg/mL to 5.0 mg/mL thrombin, 2% to 4% (w/v) sucrose, 3.5% to 5% (w/v) mannitol, 50 mM ... | 01/06/2009 |
| 7393674 | Thrombin compositions Compositions comprising thrombin and methods of preparing them are disclosed. The composition may be in the form of an aqueous solution at pH 5.7-7.4 consisting essentially of 0.1 mg/mL to 5.0 mg/mL thrombin, 2% to 4% (w/v) sucrose, 3.5% to 5% (w/v) mannitol, 50 mM ... | 07/01/2008 |
| 7371722 | Pharmaceutical preparations and medicine capable of generating and/or containing thrombin The invention relates to a pharmaceutically active substance for producing a drug that is capable of generating thrombin or that contains thrombin and compositions comprising thereof. The pharmaceutically active substance contains (A) prothrombin (coagulation factor... | 05/13/2008 |
| 7365173 | Method for the production of pure virally inactivated butyrylcholinesterase The present invention provides a method for purifying butyrylcholinesterase from various biological fluids. Biological fluids include, e.g., blood, blood fractions, plasma, and bioreactor broths, and other such mixtures containing butyrylcholinesterase. In one embod... | 04/29/2008 |
| 7354905 | Prodrugs of thrombin inhibitors There is provided compounds of formula I, R1O(O)C—CH2—(R)Cgl-Aze-Pab-R2I wherein R1 and R2 have meanings given in the description, which are useful as prodrugs of inhibitors of trypsin-li... | 04/08/2008 |
| 7351561 | Thrombin preparations and process for their production The production of a thrombin preparation which is obtained from prothrombin which is, after activation to thrombin without the addition of thromboplastin, purified by a hydrophobic interaction chromatography, it being possible subsequently also to inactivate or remo... | 04/01/2008 |
| 7268141 | Xanthine phosphodiesterase V inhibitors A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: | 09/11/2007 |
| 7223583 | Antithrombotic thrombin variants The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to varia... | 05/29/2007 |
| 7217507 | Method for detecting ligands and targets in a mixture The invention provides a method of characterizing a target that binds to a ligand. The method comprises providing ligands, optionally attached to a support, and contacting the ligands with targets to allow at least one target to bind to at least one ligand. The meth... | 05/15/2007 |
| 7118880 | Kits for screening for blood coagulation disorders In vitro methods for qualitative screening and/or quantitative determination of the functional activity of components of the Protein C anticoagulant pathway of blood coagulation are described. The methods entail measuring the conversion rate of a substrate by an enz... | 10/10/2006 |
| 7112430 | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon Provided herein are type II transmembrane serine protease 10 (MTSP10) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds... | 09/26/2006 |
| 7091325 | Fibrin/fibrinogen-binding conjugate A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or ... | 08/15/2006 |
| 7060484 | Polypeptides and coagulation therapy Novel polypeptides (NPs) are provided which are capable of protein C activation without significant fibrinogen clotting activity, and vice versa. NPs having enhanced protein C activating properties in relation to fibrinogen clotting are useful in particular as antic... | 06/13/2006 |
| 7056722 | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby A sterile method for preparing stable thrombin component from a single donor's plasma in which the thrombin component is harvested simultaneously from the clotting and adhesive proteins component from the same donor plasma in less than one hour. The combined compone... | 06/06/2006 |
| 7022521 | Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical... | 04/04/2006 |
| 7005502 | Pharmaceutical preparation comprising vWF propeptide Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWf propeptide as well as a method for producing such a prepartion. ... | 02/28/2006 |
| 6955682 | Wound closure system and methods A wound closure system and methods utilizes a patient's own blood. The system preferably includes a chamber with a needle and a plunger for transferring and storing blood prior to surgery and the use of reversible anticoagulants. The chamber is pre-loaded with a rev... | 10/18/2005 |
| 6946279 | THROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, ANHYDROTHROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, PLATELET AGGLUTINATION-INDUCING COMPOSITIONS, METHOD OF INDUCING PLATELET AGGLUTINATION, CLINICAL TEST REAGENTS, CLINICAL TEST METHOD, THROMBOSIS INHIBITORS, ADSORBENT AND PROCESS FOR PRODUCING THE SAME A thrombin derivative having a lowered fibrinogen activity, a process for producing thereof, an anhydrothrombin derivative having a lowered fibrinogen activity, and a process for producing thereof are provided. This invention is to provide a thrombin derivative form... | 09/20/2005 |
| 6943171 | Polycyclic guanine derivative phosphodiesterase V inhibitors A compound having the formula (Ia) or (b), salt or solvate thereof, with the variables as defined herein, which can inhibit selectively phosphodiesterase V and can be useful for treating sexual dysfunction and other physiological disorders, symptoms and diseases: | 09/13/2005 |
| 6936430 | Procoagulant assay Method of detecting coagulation abnormalities in a plasma sample by (a) determining a test rate of thrombin generation over a given time interval by reacting an activator of thrombin with defibrinated normal plasma in the presence of a defibrinated test plasma sampl... | 08/30/2005 |
| 6869790 | Preparation of DNA encoding factor XIIIA The cDNA which codes for factor XIIIa has been isolated using a cDNA bank from human placenta and probes constructed on the basis of the amino acid sequence of factor XIIIa peptide fragments. It is possible with this cDNA not only to obtain factor XIIIa by gene mani... | 03/22/2005 |
| 6846656 | Process for producing N-acetylneuraminic acid The present invention provides a process for economically producing N-acetylneuraminic acid without using expensive materials such as pyruvic acid and phosphoenolpyruvic acid. The process comprises: allowing (i) a culture of a microorganism having N-acetylneuraminic... | 01/25/2005 |
| 6841354 | Screening assay for anti-thrombotic/anti-platelet activity A method for screening for anti-thrombotic/anti-platelet agents is provided where the method is based on inhibition of the GP Ib, PAR-1 and/or PAR-4 pathways by the potential anti-thrombotic/anti-platelet agent. ... | 01/11/2005 |
| 6706512 | Antithrombotic thrombin variants The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to varia... | 03/16/2004 |
| 6683054 | Use of melagatran According to the invention there is provided the use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the manufacture of a medicament for the treatment of inflammation.... | 01/27/2004 |
| 6653078 | Multiplex method for nucleic acid detection Processes are disclosed using the depolymerization of a nucleic acid hybrid to qualitatively and quantitatively analyze for the presence of predetermined nucleic acid target sequences using a multiplex assay format. Applications of those processes include... | 11/25/2003 |
| 6582603 | Method for purifying thrombin substrate and/or inhibitors or method for eliminating the same A method for the refinement of a thrombin substrate, characterized by comprising therein a step of affinity chromatography formed by using an affinity adsorbent having as a ligand a thrombin or thrombin analogue deprived of nucleophilicity (activity) with... | 06/24/2003 |
| 6579537 | Method for producing fibronectin and fibrinogen compositions using a polyalkylene glycol and glycine or ଲ-alanine A method of producing a pharmaceutical preparation comprising fibronectin and fibrinogen is disclosed. The method involves admixing into a starting solution of fibrinogen and fibronectin, in a single step, a precipitating composition comprising a polyalky... | 06/17/2003 |
| 6569662 | Nucleic acids and polypeptides The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.... | 05/27/2003 |
| 6492494 | Method of making a fibrin sealant comprising alpha-2-antiplasmin The invention provides a kit for preparing a fibrin sealant either (A) comprising: (a) a fibrin monomer preparation; (b) a stabilizing preparation containing a clot-preserving effective amount of a fibrinolysis-inhibiting protein; and (c) a non-enzymatic ... | 12/10/2002 |
| 6462018 | Fibrin polymer structure In accordance with the present invention a novel fibrin polymer structure is disclosed. The novel fibrin polymer structure useful, for example, as a surgical sealant, is comprised of a plurality of discrete, droplets of polymerizing or polymerized fibrin ... | 10/08/2002 |
| 6462021 | Use of low molecular weight thrombin inhibitor According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of ischemic disorders in patients having, or at risk of, non-valvular atrial fib... | 10/08/2002 |
| 6413737 | Ecarin prothrombin protease and methods New forms of ecarin, a procoagulant protein from Echis carinatus venom, are described, as are polynucleotides encoding the new proteins, methods for production of the new proteins, and methods for activation of prothrombin using the new proteins. The new ... | 07/02/2002 |
| 6395881 | Separation of antithrombin III and ଲ variants by cyclodextrin-modified micellar electrokinetic chromatography A process is disclosed for the baseline separation of the and ଲ variants of antithrombin III AT-III. The process involves subjecting a sample comprising AT III to cyclodextrin-modified micellar electrokinetic chromatography (CD-MEKC). The CD... | 05/28/2002 |
| 6395880 | Method for purification of antithrombin III using an anion exchanger A method of purifying antithrombin III (AT III) from a starting material containing an AT III/heparin complex or an AT III/heparinoid complex is disclosed. First, the method comprises adsorbing the AT III/heparin complex or the AT III/heparinoid complex o... | 05/28/2002 |
| 6376242 | Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pha... | 04/23/2002 |
| 6284247 | Human tissue plasminogen activators Human tissue plasminogen activator (t-PA) is produced in useful quantities using recombinant DNA techniques. The invention disclosed thus enables the production of t-PA free of contaminants with which it is ordinarily associated in its native cellular env... | 09/04/2001 |
| 6262236 | Fibrin sealant compositions and methods for utilizing same The subject invention relates to fibrin sealants. More specifically, the subject invention relates to the use of a fibrin sealant wherein a composition comprising fibrin monomer or a composition comprising noncrosslinked fibrin is utilized as a component ... | 07/17/2001 |
